Compare Amgen, Inc. (AMGN) vs Bank of Montreal (BMO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Bank of Montreal — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Bank of Montreal trades at $178.77 (market cap $125.01B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Bank of Montreal is trading nearer its 52-week high, Amgen, Inc. nearer its low. Which is the better fit depends on your goals.
| AMGN | BMO | |
|---|---|---|
Market Cap | $196.12B | $125.01B |
Sector | Health | Financials |
52-Week High | $388.16 | $178.96 |
52-Week Low | $271.18 | $110.44 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 2.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
BMO trades at $178.96, up 1.3% today, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a 34% YoY net income growth in Q2 2026 and a 25.92% net margin. Recent acquisitions and dividend increases highlight strategic growth, while analyst sentiment is balanced with 44% buy ratings. The company maintains robust cash flow and a solid balance sheet with $84.25B in equity.
Outlook remains positive driven by earnings beats and expansion in metals & mining. Risks include valuation concerns at a P/E of 19.51 and interest rate sensitivity. The stock offers a steady dividend yield, but investors should monitor integration of recent acquisitions and macroeconomic pressures on banking sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Bank of Montreal
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →
